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Summary
Transgenic (Tg) mice overexpressing human wild-type
-synuclein in oligodendrocytes under the control
of the 2, 3-cyclic nucleotide 3-phosphodiesterase
(CNP) promoter are shown here to recapitulate fea-
tures of multiple system atrophy (MSA), including the
accumulation of filamentous human -synuclein ag-
gregates in oligodendrocytes linked to their degener-
ation and autophagocytosis of myelin. Significantly,
endogenous mouse -synuclein also accumulated in
normal and degenerating axons and axon terminals
in association with oligodendroglia and neuron loss
and slowly progressive motor impairments. Our studies
demonstrate that overexpression of -synuclein in
oligodendrocytes of mice results in MSA-like degen-
eration in the CNS and that -synuclein inclusions in
oligodendrocytes participate in the degeneration of
neurons in MSA.
Introduction
Growing evidence suggests that nonneuronal cells play
a role in neurodegenerative diseases. For example, ac-
tivated microglia associated with amyloid deposits in
Alzheimer’s disease (AD) may contribute to brain de-
generation (Perlmutter et al., 1990; McGeer et al., 1993),
and nonneuronal cells modulate the survival of motor
neurons expressing mutant SOD1 in amyotrophic lat-
eral sclerosis (ALS) transgenic (Tg) mouse models
(Clement et al., 2003). Astrocytes also can propagate
prion infectivity in Tg mice, where the hamster prion
protein (PrP) is expressed using the glial fibrillary acidic
protein (GFAP) promoter (Raeber et al., 1997).
Multiple system atrophy (MSA) is a neurodegenera-
tive disease that affects oligodendrocytes and neurons
in the human central nervous system (CNS). MSA is a
sporadic synucleinopathy that is characterized by ab-
normal accumulations of filamentous α-synuclein inclu-
sions in the CNS (Spillantini and Goedert, 2000; Duda
et al., 2000a; Duda et al., 2000b). These α-synuclein
inclusions, though present in the cytoplasm and nu-
cleus of neurons, are most prominent in oligodendro-
cytes, where they are known as glial cytoplasmic inclu-
sions (GCIs), and GCIs are diagnostic of MSA (Papp et
al., 1989; Arima et al., 1998; Spillantini et al., 1998; Tu et*Correspondence: vmylee@mail.med.upenn.edual., 1998). Clinically, MSA presents with Parkinsonism,
ataxia, and autonomic failure (Graham and Oppenhei-
mer, 1969). Previously, MSA was thought to be three
separate diseases known as striatonigral degeneration,
olivopontocerebellar atrophy (OPCA), and Shy-Drager
syndrome, but with recognition that GCIs are the defin-
ing lesions in all three diseases, the classification of
patients with MSA has been simplified to MSA-C (cere-
bellar ataxia) or MSA-P (parkinsonism), depending on
the relative predominance of clinical and pathological
abnormalities (Gilman et al., 1999).
Although mechanisms of neurodegeneration in MSA
are unclear, we hypothesize that oligodendrocytic de-
generation is a consequence of α-synuclein inclusions
and that GCIs contribute significantly to neuronal de-
generation in MSA. Since accumulations of human
wild-type α-synuclein in neurons led to the formation
of neuronal α-synuclein aggregates and dopaminergic
degeneration in a mouse model of Parkinson’s disease
(Masliah et al., 2000), accumulation of α-synuclein in
CNS oligodendrocytes may be linked to mechanism(s)
underlying MSA. To examine this possibility, we have
generated a Tg mouse model that expresses human wild-
type α-synuclein in oligodendrocytes of the mouse CNS
(Giasson et al., 2003) under the control of the 2#, 3#-
cyclic nucleotide 3#-phosphodiesterase (CNP) promoter
(Gravel et al., 1998). Since oligodendrocytes in the Tg
mice developed age-dependent accumulations of hu-
man α-synuclein into GCIs concomitant with brain de-
generation, we asked if oligodendrocytic degeneration
also causes neuronal degeneration. Here, we demon-
strate that the formation of GCI-like α-synuclein inclu-
sions leads directly to neuronal degeneration as exem-
plified by motor impairments and novel accumulations
of endogenous mouse α-synuclein in the brain and spi-
nal cord. The motor impairments were associated with
the degeneration of oligodendrocytes and axons in the
CNS, indicating that the Tg mice developed a neurode-
generative synucleinopathy with close verisimilitude to
authentic MSA. Thus, our study shows that the accu-
mulation of α-synuclein as GCIs can lead to neurode-
generation in Tg mice, and we suggest that similar pro-
cesses underlie MSA.
Results
Generation of Tg Mice Expressing Human Wild-Type
-Synuclein in Oligodendrocytes
The murine CNP promoter was used to drive expres-
sion of human α-synuclein in oligodendrocytes of Tg
mice (M2 mice) (see Figure 1A) (Gravel et al., 1998). Im-
munoblotting analysis with antibodies against human
α-synuclein demonstrated the expression of this
transgene in the brain of M2 mice (Figure 1B). Since
endogenous α-synuclein is predominantly found in
neurons with very low levels expressed in oligodendro-
cytes, it was not possible to determine the level of hu-
man α-synuclein overexpression in oligodendrocytes in
our Tg mice. However, the overall human α-synuclein
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848Figure 1. Expression of Human α-Synuclein in M2 Mice
(A) Schematic representation of the cDNA construct used to generate Tg mice expressing human α-synuclein in CNS oligodendrocytes under
the control of the murine CNP promoter.
(B) Immunoblotting analysis of α-synuclein expression in an 8-month-old non-Tg mouse (lane 1; 8 Mo. non-Tg), a 3-month-old M2 mouse
(lane 2; 3 Mo. M2), and an 8-month-old M2 mouse (lane 3; 8 Mo. M2). Total protein brain homogenates were separated on SDS-PAGE gels,
and blots were analyzed with three anti-α-synuclein antibodies (Syn204, LB509, and SNL1). SNL1 detects both murine and human α-synuclein;
Syn204 selectively recognizes human α-synuclein; and LB509 is specific for human α-synuclein. Immunoblotting for actin was used as a
loading control.
(C) Double-label immunofluorescence staining of white matter of the spinal cord in 18-month-old M2 (C1–C3) and age-matched nontransgenic
(C4–C6) mice. CNP colocalizes with α-synuclein (SNL1) in the cytoplasm of the oligodendrocytes in M2 mice (arrows). Scale bar, 15 m.
(D) In situ hybridization was used to assess the expression of α-synuclein mRNA in 12-month-old M2 and age-matched non-Tg mice.
Micrographs of emulsion-dipped in situ hybridization with two probes specific for human α-synuclein mRNA show that human α-synuclein is
expressed only in oligodendrocytes (arrowheads), but not in neurons (arrows) (D1 and D2). In contrast, the in situ hybridization using a probe
specific for mouse endogenous α-synuclein mRNA reveals that mouse α-synuclein is expressed in neurons (arrows), but not in oligodendro-
cytes (arrowheads), in the M2 Tg (D3) and in non-Tg control mice (D4). Scale bar, 6 m.
(E) Immunohistochemical analysis of cerebral cortex (cerebrum) and spinal cord in 3-month-old M2 (E1 and E4) and 18-month-old M2 Tg
mice (E2 and E5), and age-matched controls (E3 and E6). SNL1 staining shows the typical neuropil distribution of α-synuclein in addition to
α-synuclein expression in oligodendrocytes of M2 Tg mice, but not in oligodendrocytes of non-Tg mice. No pathological change is observed
in the neuropil of M2 Tg mice at 3 months, but accumulations of α-synuclein are detected in the neuropil at 18 months. Scale bar, 15 m.
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849overexpression in oligodendrocytes was relatively low,
since the levels of total α-synuclein (both human and
endogenous mouse) expression as detected by SNL1
did not differ significantly between non-Tg and the M2
Tg line (Figure 1B). Northern analysis of Tg human and
endogenous mouse α-synuclein mRNA in M2 and non-
Tg mouse brain indicated that the levels of human
α-synuclein mRNA were much less than those of en-
dogenous mouse α-synuclein in M2 Tg mice (Figure
S1). Nevertheless, we observed an age-dependent
increase in human α-synuclein in total brain homoge-
nates from the M2 mice, suggesting an accumulation of
α-synuclein protein in oligodendrocytes as the animals
aged. To demonstrate that the cells expressing human
α-synuclein were indeed oligodendrocytes in M2 mice,
double-label immunofluorescence staining was con-
ducted with anti-α-synuclein and anti-CNP (a marker
of oligodendrocytes) antibodies. The colocalization of
human α-synuclein with CNP confirmed that oligo-
dendrocytes are the only cells that express human
α-synuclein (Figure 1C). In situ hybridization with two
human α-synuclein-specific probes revealed the selec-
tive presence of human α-synuclein mRNA in oligoden-
drocytes but not in neurons of M2 mice (Figure 1D). The
distribution of human α-synuclein in oligodendrocytes
was analyzed next by immunohistochemistry in brain
and spinal cord of 3-, 10-, 18-, and 24-month-old M2
mice, and we demonstrated that α-synuclein also accu-
mulated in the neuropil with increasing age (Figure 1E2
and 1E5).
CNP--Synuclein M2 Mice Develop Age-Related
Motor Impairments and Neurodegeneration
To assess if the expression and progressive accumula-
tion of human α-synuclein in oligodendrocytes give rise
to a clinical phenotype, we examined the motor func-
tion of M2 mice. Tg mice did not exhibit any motor im-
pairment on a flat surface except for slow motor activity
when compared with non-Tg mice. However, when M2
mice were subjected to other motor testing paradigms,
they showed several distinct motor impairments when
compared with age-matched non-Tg mice (Figures 2A
and 2B). For example, the rotarod treadmill test re-Figure 2. Motor Impairment in M2 Mice
(A) Rotarod treadmill test documenting impaired motor performance in M2 Tg mice compared to non-Tg mice. Motor impairment in M2 mice
starts between the ages of 7 and 9 months. Error bars show the standard error of the means. **p < 0.01, Student’s t test.
(B) Wire hanging test demonstrating impaired motor ability in M2 mice by 7 months of age (**p < 0.01).vealed a decrease in the endurance time for motor per-
formance beginning at 7–9 months of age (Figure 2A).
However, the weekly rotarod test in mice examined
from 6 weeks to 32 weeks showed no significant differ-
ence between M2 and non-Tg mice (data not shown),
consistent with an age-related rather than a develop-
mental motor abnormality in M2 mice. To assess pure
muscle strength of mouse forepaws, the mice were ex-
amined in a wire hanging test. This test confirmed a
progressive reduction in grip strength of M2 mice with
advancing age (Figure 2B), and this was associated
with progressive brain atrophy (Figure 3A). Quantitative
analysis of brain weight in M2 (n = 5) and control non-
Tg (n = 5) mice demonstrated a 16% reduction at 24
months of age (p < 0.01) and an 8.8% decrease at 9
months of age (p < 0.01) in M2 mice (Figure 3B). There
was no significant change in brain weight between M2
and non-Tg mice at 1 and 3 months of age, thereby
indicating no developmental abnormality in M2 mice.
The brain atrophy reflected a reduction in the neuropil
and white matter, which most likely resulted from cell
loss in M2 mice (Figure 3C). Despite this reduction in
brain size, the life span of M2 mice was not affected
compared with non-Tg mice. At the age of 24 months,
the survival rate was 89% in M2 mice (n = 36) and 83%
in control non-Tg mice (n = 30). The longest survival
span was 33 months in M2 mice and 34 months in con-
trols.
To assess if the motor impairments are associated
with oligodendrocytic and/or neuronal degeneration in
M2 mice, quantitative analyses of oligodendrocytes
and neurons in the spinal cord were performed in 24-
month-old M2 Tg and age-matched non-Tg control
mice. These analyses showed a decrease in the num-
ber of oligodendrocytes and neurons in the M2 mice
compared to the non-Tg mice (Figure 3E). In particular,
neuronal loss was most prominent in the lateral and
medial columns of M2 mice (Figure 3D). Quantitative
analyses of dopaminergic neurons, however, showed
no decrease in M2 mice (data not shown).
Pathological Changes in the CNS of M2 Mice
Since human α-synuclein accumulates in oligodendro-
cytes as GCIs in an age-dependent manner during MSA
Neuron
850Figure 3. Expression of α-Synuclein in Oligo-
dendrocytes Causes Brain Atrophy
(A) At 24 months of age, gross brain atrophy
is evident in M2 Tg mice.
(B) Brain weight is progressively reduced in
M2 mice. Error bars show the standard error
of the means. **p < 0.01.
(C) Microscopic features of brain atrophy in
24-month-old M2 mouse compared to age-
matched non-Tg control mice using Luxol
fast blue stain with cresyl violet. In the
atrophic brain of M2 mouse, note that the
neuropil in the cerebral cortex is shrunk, and
the white matter is reduced. Scale bar,
200 m.
(D) Immunofluorescence study using NeuN
shows a decrease of neurons in the spinal
cord of 24-month-old M2 mice compared to
age-matched non-Tg mice. Arrows show
significant decreases of neurons, especially
in the areas of lateral and medial columns of
the spinal cord in the M2 mice. Scale bar,
150 m.
(E) Bar graphs comparing the numbers of
neurons and oligodendrocytes in the spinal
cord of the M2 and non-Tg control mice. The
number of the neurons and oligodendro-
cytes are reduced in the M2 mice. *p = 0.024
(neuron), *p = 0.018 (oligodendrocyte), Stu-
dent’s t test.progression, we compared the α-synuclein inclusions s
tin our M2 mice with GCIs from MSA patients, and we
found that many of the α-synuclein aggregates in M2 a
umice resembled authentic GCIs in MSA (Figures 4A and
4B). Moreover, like MSA, α-synuclein accumulations e
ralso occurred in the neuropil (Figure 4A and Figure 1C).
Although neuronal perikarya in the brain and spinal cord d
dof M2 mice showed no immunoreactive α-synuclein ag-
gregates, a Mab specific for highly phosphorylated d
nhigh-apparent molecular weight (Mr) neurofilament sub-
unit (NF-H) proteins (RMO24) showed strong phosphor- i
cylated NF-H immunoreactivity in neuronal perikarya in
addition to axons (Figures 4C and 4D; Figures S2A and a
cS2B). Since phosphorylated NF-H proteins normally are
found only in axons and not in neuronal perikarya, but a
a redistribution of highly phosphorylated NF-H from ax-
ons to perikarya has been linked to neuronal injury I
i(Sternberger et al., 1985; Goldstein et al., 1987), we
conclude that NF-H-positive neurons in our M2 mice S
iare injured and possibly degenerating. This view is also
supported by the detection of axonal spheroids with α
iRMO24 in the cortex of M2 mice indicative of axonal
degeneration (Figure 4E), and these spheroids were not M
qseen in control animals (Figure 4F). Other evidence inupport of degeneration included remarkable gliosis in
he brain as well as in the spinal cord detected by an
nti-GFAP antibody using immunohistochemistry (Fig-
res 4G and 4H; Figures S2C and S2D). In addition, ab-
rrant growth-associated protein 43 (GAP43) immuno-
eactivity surrounding neuronal perikarya, which is
istinctly abnormal and indicative of axons and den-
rites undergoing regeneration after injury, was also
etected by an antibody against GAP43 (Figure 4I). Sig-
ificantly, similar abnormal neuronal perikaryal reactiv-
ty to anti-GAP43 antibody was observed in Purkinje
ells of human MSA brains (Figure 4K). In spinal cord of
ge-matched control mice and Purkinje cells of human
ontrols, anti-GAP43 antibody did not show immunore-
ctivity (Figures 4J and 4L).
nsoluble -Synuclein Accumulates
n an Age-Dependent Manner in M2 Mice
ince insoluble aggregated α-synuclein accumulates
n brains of MSA patients, we serially extracted
-synuclein from brains of M2 mice using methods sim-
lar to those developed for the extraction of human
SA brain tissue (Duda et al., 2000a). Following the se-
uential extraction of CNS tissue with buffers of
Neurodegeneration in a Mouse Model of MSA
851Figure 4. Pathological Changes in the CNS of M2 Tg Mice
(A and B) Immunohistochemical staining of tissue sections of cerebral white matter from 24-month-old M2 mice (A) and patients with MSA
(B) using anti-α-synuclein antibody (Syn). Note the presence of GCI-like inclusions as well as the accumulation of α-synuclein in oligodendro-
cytes and the neuropil in M2 mice (A). These inclusions are similar to GCIs in patients with MSA (B).
(C and D) Numerous neurons of the spinal cord of M2 mice are immunoreactive for hyperphosphorylated neurofilament (NF-H) using RMO24
antibody (C), but neurons of age-matched control mice do not show any immunoreactivity with the RMO24 antibody (D).
(E and F) Axonal spheroids in the cerebral cortex of M2 mice are demonstrated by RMO24 staining (E), but no spheroids are found in the
cerebral cortex of age-matched control mice (F).
(G and H) Anti-GFAP staining shows gliosis in the cerebral cortex (G) and spinal cord (H) of M2 mice.
(I and J) Neuronal perikarya in M2 mice are immunoreactive to anti-GAP43 antibody (GAP) (I), but no neuronal staining of anti-GAP43 antibody
is shown in age-matched control mice (J).
(K and L) A Purkinje cell in the affected cerebellum of an MSA patient shows immunoreactivity to anti-GAP43 antibody (K), but no Purkinje
cell in human controls shows similar immunoreactivity (L). Scale bar, 10 m.increasing protein extractability, human α-synuclein in
CNS samples of M2 mice at the ages of 6, 12, 18, and
24 months were assayed by immunoblotting. Spinal
cord and different brain regions (i.e., cerebrum, cerebel-
lum, brain stem) were examined separately, and each
region was serially extracted into three fractions of high
salt (HS), RIPA, and formic acid (FA). Immunoblots of
fractions from all four of these CNS regions of M2 mice
were performed using the Mab Syn204, and this anti-
body detected human α-synuclein expression in all re-
gions examined (Figures 5A and 5B). Since human
α-synuclein was expressed at higher levels in the spinal
cord and cerebrum, insoluble α-synuclein was also de-
tected in FA fractions of these regions (Figures 5A and
5B). Some high-Mr insoluble α-synuclein species did
not enter the resolving SDS-PAGE gels, and they began
to accumulate in the CNS of M2 mice at 6 months of
age and increased significantly in the spinal cord of 12-
month-old and older mice (Figure 5B). Aggregated
α-synuclein was partially resistant to FA solubilization,
as shown by multiple bands of high-molecular mass
species on the immunoblots (Figures 5A and 5B). Sim-
ilar profile of α-synuclein insoluble aggregates were
also detected by SNL1, a α-synuclein antibody that rec-
ognized both human and mouse α-synuclein in M2 but
not in non-Tg mice (Figure 5B).
To compare the α-synuclein insolubility in M2 micewith that in MSA patients, samples of pons from pa-
tients with MSA and human controls were similarly ex-
tracted sequentially into three fractions of HS, RIPA,
and FA. Immunoblotting with anti-α-synuclein Mab de-
tected multiple bands of insoluble α-synuclein (includ-
ing high-Mr aggregates at the top of gels) in the FA
fraction of MSA but not in the pons of control patients
(Figure 5C). Thus, the pattern of FA-extracted insoluble
human α-synuclein from MSA brains and from our M2
mice bear striking similarities.
-Synuclein-Induced Oligodendrocytic
Degeneration Causes Demyelination
and Secondary Axonal Degeneration
The effects of human α-synuclein accumulation and
aggregation on oligodendrocytes were assessed ultra-
structurally. Samples of cerebrum, pons, cerebellum,
and spinal cord in M2 mice at the ages of 10 and 24
months were examined using transmission electron mi-
croscopy (EM) (Figure 6) and immuno-EM (Figure 7).
Oligodendrocytes, which were immunoreactive with hu-
man-specific anti-α-synuclein Mab LB509 in preem-
bedding immuno-EM (Figure 7G), contained degraded
myelin and extensive accumulations of lysosomes (Fig-
ures 6A and 6B) as well as fragmented myelin in their
cytoplasm (Figures 6C and 6D). This suggests that au-
tophagocytosis of degenerated myelin occurred in dis-
Neuron
852Figure 5. Insoluble α-Synuclein Accumulates in CNS of M2 Mice
(A) The CNS of M2 mice at the age of 6 months, 12 months, and 24 months was divided into four regions: cerebrum, cerebellum, brain stem,
and spinal cord. Tissues from all four regions were sequentially extracted with HS, RIPA, and FA as described in the Experimental Procedures.
Immunoblotting analysis with the human α-synuclein-specific antibody Syn204 shows insoluble α-synuclein in the FA fractions of the 12- and
24-month-old M2 mice (arrow) in addition to soluble α-synuclein in the HS and RIPA fractions. Aggregated α-synuclein that is resistant to FA
appears as high-Mr bands within the resolving and stacking gels (arrowheads); since Syn204 is human α-synuclein specific, control mice
showed no Syn204-immunoreactive bands (data not shown).
(B) Immunoblots of spinal cord serially extracted with HS, RIPA, and FA from M2 mice at the ages of 6, 12, 18, and 24 months and a non-Tg
mouse at the age of 24 months conducted with Syn204 and SNL1. Insoluble α-synuclein in the FA fraction appears as multiple bands, which
include aggregated α-synuclein at the top of gels in M2 mice at the age of 12 months and older on the immunoblots when stained with
Syn204 (arrowhead). Mr is indicated on the right.
(C) Pontine tissues of MSA patients (M) and human controls (C) were sequentially extracted with HS, RIPA, and FA. Immunoblot analysis of
these extracts with LB509 antibodies shows that insoluble α-synuclein is detected only in the FA fraction of brain extracts from MSA patient
(arrow). As compared to the insoluble α-synuclein in M2 mice, a similar pattern of aggregated α-synuclein is recognized as high-Mr multiple
bands in MSA brain tissues (arrowheads). No insoluble α-synuclein is detected in the FA fraction of human controls. Mr is indicated on
the right.eased oligodendrocytes. α-synuclein immunopositive e
mfilaments were detected in the cytoplasm of oligoden-
drocytes in M2 mice (Figures 7A–7C and 7G), indicating S
nthat oligodendrocytic degeneration may result from the
aggregation of α-synuclein in M2 mice. These GCI-like α
tfibrillar aggregates contained filaments that were ap-
proximately 10–15 nm in diameter (Figure 7C). Degener- c
nated myelin sheaths associated with degenerating ax-
ons were observed in the CNS, most prominently in the o
ospinal cord (Figure 6E). Accumulation of α-synuclein
also was found within the degenerating myelin sheath m
m(Figure 7H).
Neuronal cell bodies were not immunostained with i
any of anti-α-synuclein antibodies in M2 mice (Figure
7F and data not shown). Unexpectedly, SNL1, an anti- a
abody that recognizes endogenous mouse synuclein, de-
tected α-synuclein ectopically deposited within a large (
anumber of axons (Figure 7E). Indeed, 73% of the total
axons counted (n = 895) in the spinal cord of M2 mice at c
r24 months of age were immunostained by SNL1. How-ver, in the spinal cord of age-matched controls, im-
uno-EM detected α-synuclein immunoreactivity with
NL1 only very rarely in axons (1.8% of the total axons;
= 538). Significantly, LB509, a Mab specific for human
-synuclein, did not immunostain axons of M2 mice or
he brains and spinal cords of control mice. Thus, we
onclude that endogenous mouse α-synuclein recog-
ized by SNL1 ectopically accumulated within CNS ax-
ns of the M2 mice. To further characterize the nature
f this accumulation, we conducted higher-power im-
uno-EM with SNL1 and showed that endogenous
ouse α-synuclein accumulated as fibrils within axons
n M2 mice (Figures 7J and 7K).
Ultrastructural analysis of spinal ventral roots in M2
nd non-Tg control mice showed a loss of myelinated
xons and sprouting of unmyelinated axons in M2 mice
Figures 6J–6L), indicating neuronal degeneration in the
nterior horn of the spinal cord. Indeed, degenerative
hanges also were detected by EM in spinal cord neu-
ons of M2 mice (Figure 7F). Taken together, these data
Neurodegeneration in a Mouse Model of MSA
853Figure 6. Transmission EM Analysis of M2
Mice
(A) A degenerating oligodendrocyte in cere-
bral cortex of a 24-month-old M2 mouse.
The cytoplasm is largely occupied by sec-
ondary lysosomes. The nucleus (n) is irregu-
lar. (B) Higher magnification of a secondary
lysosome in the oligodendrocyte shown in
(A) also demonstrates that the lysosomes
contain lamellar structures of degenerated
myelin. (C) An oligodendrocyte in the spinal
cord of a 24-month-old M2 mouse displaying
unusual pathological organelles, including
fragmented myelin and some rod-like cyto-
plasmic structures (arrowheads). There also
are secondary lysosomes in the cytoplasm
(asterisks). (D) High-power magnification of
an oligodendrocyte, revealing a lysosome
associated with fragmented myelin in the
cytoplasm (arrows), indicating autophago-
cytosis of degraded myelin. (E) Micrograph
showing degeneration of a myelinated nerve
fiber in the spinal cord of a M2 Tg mouse.
Note the dilated myelin sheath and the
frayed layers of myelin in the enlarged space
between the outer myelin and the axon. Also
note that the remains of the axon within
the degenerated myelin contain amorphous
structures with enlarged mitochondria. (F)
Low-power EM view of an abnormal inclu-
sion in the spinal cord of an M2 mouse. The
boxed area is seen at higher power in (I). The
inclusion is surrounded by a membrane and
is mostly occupied by disordered tubular
structures. (G) Features of the inclusions are
also observed in axon terminals of the spinal
cord of M2 mice. The axon terminal contains
synaptic junctions and degenerated synap-
tic vesicles, abnormally large vesicles and
mitochondria. The terminal is mostly occu-
pied by disordered tubules. (H) A higher-
power view of the boxed-in area in (G), which
confirms synaptic junctions in the axon terminal (arrows). The disordered tubules in the terminal are approximately 20–35 nm in diameter
(arrowheads), and they are also immunolabeled with the anti-α-synuclein antibodies (see Figure 7O). (I) High-power view of boxed-in area in
(F), showing that the inclusion is comprised of disordered tubules (arrowheads) and amorphous dense structures among the tubules. The
tubules are approximately 20–35 nm in diameter, and each shows a dense wall surrounding a lighter core when they are sectioned trans-
versely. (See Figure 7O for immunolabeled tubules). (J–L) Transverse sectioned ventral roots of 24-month-old M2 (K and L) and age-matched
non-Tg (J) mice. In M2 mice (K), the density of myelinated axons (a) is decreased, and some of the myelinated axons have thin myelin (a1).
Magnifications of (J) and (K) are the same. In high magnification of the ventral root of M2 mice, sprouting axons (sa) are seen by bundles of
small, closely packed unmyelinated axons, indicative of axonal degeneration (K). Scale bars, 10 m (J); 2 m (A, E, and L); 500 nm (C, F, and
G); and 100 nm (B, D, H, and I).show that axons accumulate endogenous mouse
α-synuclein in response to human α-synuclein-induced
oligodendrocytic degeneration in M2 mice.
Surprisingly, a different type of inclusion containing
disordered tubular structures, approximately 25–35 nm
in diameter, was identified in the spinal cord of M2 mice
using transmission EM (Figures 6F and 6I). Since the
same appearance of disordered tubular structures was
observed in the degenerating axon terminals in the spi-
nal cord (Figures 6G and 6H), these pathological inclu-
sions may be derived from degenerating axon terminals.
The degenerating axon terminals, which showed accu-
mulations of α-synuclein (Figures 7I and 7L), increased
in number and size in older M2 mice, and they were not
observed in the brains (data not shown) and spinal
cords of the age-matched non-Tg mice (Figure 7D). The
axon-terminal inclusions were morphologically and im-munochemically distinct from the oligodendrocytic in-
clusions (compare Figures 7A–7C with Figures 7M–7O).
For example, while the human α-synuclein fibers in the
oligodendrocytic inclusions were stained with the hu-
man-specific anti-α-synuclein Mab LB509 (Figures 7B
and 7C), the tubular structures in the axon-terminal in-
clusions were not decorated by LB509 but instead only
reacted with the antibodies that recognized both en-
dogenous mouse and human α-synucleins (SNL1) (Fig-
ure 7O).
That mouse α-synuclein accumulated in axons and
nerve terminals of M2 mice was further confirmed by
immunohistochemistry in spinal cord sections using
7544, a mouse-specific α-synuclein antibody (Figures
8A and 8B). Since endogenous mouse α-synuclein is
present at low level in the spinal cord, 7544 weakly im-
munostained spinal cord sections from non-Tg mice.
Neuron
854Figure 7. Immuno-EM Analysis of M2 Mice
(A) Accumulation of α-synuclein in an oligo-
dendrocyte in the spinal cord of a 24-month-
old M2 mouse. Anti-α-synuclein antibody,
Syn204, detects fibrillary accumulation of
α-synuclein in the cytoplasm and the process.
(B) Higher magnification of the inclusion in
the large boxed-in area in the oligodendro-
cyte in (A), showing fibrillary inclusions (ar-
rowheads). (C) Higher magnification of the
process of the oligodendrocyte in the small
boxed area in (A). Fibrils of α-synuclein are
approximately 10–15 nm in diameter and are
morphologically distinguished from the dis-
ordered tubules that make up the inclusions
found in axon terminals (see Figure 7O). (D
and E) Immunoreactivity of SNL1, an anti-α-
synuclein antibody that recognizes mouse
endogenous α-synuclein, in axons (a) of spi-
nal cord of 24-month-old M2 (E) and age-
matched non-Tg control (D) mice. Immuno-
detection with SNL1 reveals that α-synuclein
ectopically accumulates within axons of M2
TG mice (E). SNL1 displays no immunoreac-
tivity in axons (a) or axon terminal (at) in con-
trol non-Tg mice (D). (F) α-synuclein is not de-
tected in neuronal perikarya in the spinal cord
of an M2 mouse. A neuron is darkened, and
the cytoplasm contains vacuoles, indicating
neuronal degeneration. (G) α-synuclein accu-
mulation in an oligodendrocyte in the spinal
cord of a 24-month-old M2 mouse detected
by LB509, a human-specific anti-α-synuclein
antibody. Human α-synuclein is detected in
the cytoplasm and its inclusion of the oligo-
dendrocyte but is not detected in the axons.
Higher magnification of the inclusion in the
boxed area is shown in the inset in the left
lower corner (scale bar, 500 nm). The inclu-
sion contains α-synuclein fibrils. (H) SNL1
shows α-synuclein accumulation within de-
generating myelin of an M2 mouse spinal
cord. α-synuclein has accumulated in de-
generating myelin (m) with vacuoles (v) (ar-
rows). The axons (a) show ectopic accumu-
lation of α-synuclein. (I) A degenerating axon
terminal in the spinal cord of a 24-month-old
M2 mouse demonstrates strong immunore-
activity to SNL1. (J) Ectopic accumulation of
α-synuclein in an axon (a) forms fibrils in the
spinal cord of an M2 mouse detected with
SNL1. (K) Higher magnification of the boxed
area in the axon in (J) demonstrates that
SNL1 detects individual fibrils, approximately 10–15 nm in diameter (arrowheads). (L) Higher magnification view of the degenerating axon
terminal in the boxed area in (I) shows that the terminal is enlarged by accumulation of α-synuclein fibrils (arrowheads) and disordered tubular
structures with mitochondria (m). (M) An abnormal inclusion in axon terminal in the spinal cord of a 24-month-old M2 mouse is stained with
SNL1. (N) Middle magnification of the inclusion (M) shows that the inclusion is mostly composed by disordered tubules. (O) In high magnifica-
tion of the inclusion (M), the inclusion contains 25–35 nm tubules that are immunolabeled with SNL1 (arrowheads). Scale bars, 2 m (A, F, G,
and M); 500 nm (B, D, E, H–L, and N); and 100 nm (C and O).In sharp contrast, 7544 detected mouse α-synuclein in i
aaxons and in axonal terminals around spinal cord motor
neurons in M2 Tg mice. These accumulations of mouse w
α-synuclein in the spinal cord of M2 mice are specific,
since anti-synaptophysin antibodies did not immuno- D
stain these aberrant nerve terminals but weakly stained
the degenerating axons (data not shown). Furthermore, W
pincreased mouse α-synuclein at synaptic terminals in
the hippocampus of M2 mice was detected by SNL1 h
owhen compared with non-Tg mice (Figures 8C and 8D).
Taken together, these data suggest that the α-synuclein inclusions that we observed here in the degenerating
xon terminals as well as within the axons of M2 mice
ere comprised of endogenous mouse α-synuclein.
iscussion
e have demonstrated here that the M2 Tg mice ex-
ressing human α-synuclein in oligodendrocytes ex-
ibited a primary oligodendrocytic as well as a sec-
ndary neuronal degenerative phenotype with motor
mpairments similar to MSA. This motor behavioral defi-
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855Figure 8. Abnormal Accumulation of Endogenous Mouse α-Synuclein
in Axons and Axon Terminals of M2 Mice
(A and B) Immunohistochemical study using 7544, a mouse
α-synuclein-specific antibody in the spinal cord of 24-month-old
M2 (A) and age-matched non-Tg mice (B). Note that α-synuclein
immunoreactivity was detected in the nerve terminals (arrowheads)
and axonal inclusions (arrow) but not in the oligodendrocytes of
the M2 mouse.
(C and D) SNL1 detected more α-synuclein immunoreactivities in
synaptic terminals of M2 hippocampus (C) than in those of non-Tg
control (D). Scale bar, 6 m.cit was associated with the accumulation of human
α-synuclein aggregates in oligodendrocytes as well as
endogenous mouse α-synuclein in axons and axon ter-
minals. M2 mice showed progressive brain atrophy, and
immunohistochemistry using anti-α-synuclein antibod-
ies demonstrated that M2 mice developed GCI neuro-
pathology similar to MSA. Biochemical analyses of se-
quentially extracted CNS tissues of M2 mice using
buffers of increasing strengths showed accumulations
of insoluble α-synuclein. Similar high-Mr species of in-
soluble α-synuclein (Tu et al., 1998; Dickson et al., 1999;
Duda et al., 2000a), including the presence of α-synuclein
aggregates at the top of gels, have been detected in
brains of MSA patients and in our M2 mice using immu-
noblots. Although a Tg mouse expressing α-synuclein
in oligodendrocytes driven by the proteolipid protein
promoter (PLP) was shown to develop α-synuclein con-
taining GCI-like inclusions, the formation of α-synuclein
filaments, motor impairment, and secondary neurode-
generation was not reported in these Tg mice (Kahle et
al., 2002). The lack of neurodegeneration in the PLP-
α-synuclein Tg mice could be due to the different
promoters used to drive α-synuclein expression or in-
sufficient expression levels of α-synuclein in oligoden-
drocytes. Thus, our M2 mice not only recapitulated
many features of MSA neuropathology but also pro-
vided evidence that secondary neuronal degeneration
can occur as a direct consequence of oligodendrocytic
GCI-like pathologies. This finding is extremely important
in assessing the contribution of GCIs versus neuronal
α-synuclein inclusions to the neurodegeneration in
MSA, and our M2 mice would therefore serve as a use-ful Tg mouse model of MSA. Other examples of axonal
degeneration mediated by glial pathologies include
multiple sclerosis, which causes axonal degeneration
with demyelination in human CNS (Trapp et al., 1998),
and a hereditary form of peripheral neuropathy, which
shows axonal involvement with myelin degeneration
(Bergoffen et al., 1993), while axonal degeneration also
was demonstrated in PLP-deficient mice (Griffiths et
al., 1998).
We observed significant oligodendroglia and neuron
loss in spinal cord and cortical areas in the M2 mice,
and the distribution of neuronal loss in the spinal cord
showed similarity to human MSA pathology (Papp and
Lantos, 1994). The lack of overt degeneration in cere-
bellum and the pontine nuclei may be due to the lower
levels of α-synuclein expression, since our biochemical
analyses showed much lower levels of α-synuclein in
cerebellum than in cortex and spinal cord. We also ob-
served significant demyelination in the M2 mice. Al-
though pronounced demyelination in MSA was not ob-
served using conventional methods such as Luxol fast
blue, widespread myelin degeneration in MSA was ob-
served using antibodies that recognized a specific epi-
tope in human myelin basic protein (Matsuo et al.,
1998). Thus, demyelination in M2 mice is another fea-
ture consistent with MSA.
Evidence was provided to document neuronal de-
generation in our M2 Tg mice. For example, pathologi-
cal changes were also observed in neuronal cell bodies,
which accumulated phosphorylated NF-H immunoreac-
tivity, a marker of neuronal injury, since the phosphory-
lated NF-H proteins are normally restricted to axons in
healthy neurons. However, in several neurological dis-
eases and in experimental models of axotomy, phos-
phorylated NF-H proteins have been detected in neu-
ronal perikarya (Klosen et al., 1990), and therefore the
translocation of phosphorylated NF-H from axons to
cell bodies is a signature of the reaction of neurons to
axonal injury (Hedreen and Koliatsos, 1994). Further
evidence in support of axonal damage and hence axo-
nal degeneration include the presence of phosphory-
lated NF-H-immunoreactive axonal spheroids and the
increased expression of GAP43 in neurons of the M2
mice. Significantly, similar neuronal changes also were
observed in the brains of MSA patients here. Ultrastruc-
tural studies of the spinal cord and ventral root demon-
strated axonal sprouting indicating axonal and neuronal
degeneration in M2 mice.
Transmission EM and immuno-EM analyses using anti-
α-synuclein antibodies demonstrated that two types of
inclusions coexisted in the CNS of M2 mice. One type
of α-synuclein aggregate was found in the cytoplasm
of oligodendrocytes associated with degeneration. These
inclusions were filamentous, as demonstrated by immuno-
EM, and they resulted from the accumulation of human
α-synuclein that was expressed in the oligodendrocytes
under the control of the CNP promoter. Ultrastructurally,
these filamentous inclusions resembled those identified
in Tg mice expressing human A53T α-synuclein in neu-
rons under control of the PrP promoter (Giasson et al.,
2002). A second type of inclusion localized to the axons
and axon terminals had a tubular ultrastructural ap-
pearance, in which endogenous mouse α-synuclein
was a component. Accumulation of the endogenous
Neuron
856mouse α-synuclein also was detected in the degener- o
ated axon terminals and the axons themselves, indicat- h
ing axonal degeneration. However, it is unclear why en-
dogenous mouse α-synuclein accumulated selectively E
within axons and their terminals. It is possible that this
Gmay represent a specific neurodegenerative response to
Thuman α-synuclein-induced oligodendroglia degenera-
otion, or a regenerative response to axonal injury caused
sby degenerating oligodendrocytes. Nevertheless, since
r
the most distal segment of the axon affected was the i
axon terminal, which is where α-synuclein is physiologi- e
cally localized (George et al., 1995; Iwai et al., 1995; Jakes b
aet al., 1994), aggregation of neuronal mouse α-synuclein
zlikely begins at axon terminals. Morphologically, the
aaxon-terminal inclusions occupied by the disordered
tubules show some resemblance to the microtubular
Iaccumulations reported in GCIs of MSA patients (Naka-
Tzato et al., 1990; Yamada and McGeer, 1990).
pM2 mice exhibited another interesting feature of the
T
MSA phenotype, since they also showed motor impair- a
ments between 7 and 9 months of age and developed R
pathology in the CNS between 3 and 10 months of age. a
(Thus, the onset of degeneration is suspected to be be-
btween 3 and 6 months of age in the M2 mice. Although
pM2 mice showed an early onset of the disease process,
D
these mice did not show any statistically significant dif- a
ference in life span compared to non-Tg mice. For this t
reason, we speculate that the motor impairments in M2 α
0mice were sufficiently mild such that they did not com-
dpromise the life span of these mice and/or that the dis-
eease process in the M2 mice is slow. Because the dis-
ease is progressive in the CNS and the onset is very
Iearly in the life span of the M2 mice, the latter explana-
Ttion seems more plausible. It is clear that the M2 mice
asurvive longer than Tg mice overexpressing human
cA53T α-synuclein under the control of the PrP pro-
G
moter, since 100% of the latter mice die between 7 and t
16 months (Giasson et al., 2002). A
The slow disease progression seen in M2 mice may m
ube explained as a two-step process; oligodendrocytic
Cdegeneration occurs first, and axonal degeneration oc-
6curs second. Since axonal degeneration is an indirect
A
process related to the oligodendrocyte pathology, axo-
nal neuropathology may take longer to develop. The p
slowly progressive disease course also was charac- a
terized by autophagocytosis in the oligodendrocytes
and unique structural inclusions in the axon terminals. M
Although oligodendrocytes are known to form myelin R
sheaths by their processes (Peters et al., 1991), auto- T
phagocytosis of fragmented myelin is a pathological a
wfeature that is rarely observed under normal conditions.
3The M2 mouse line may be a very informative animal
tmodel for studying and understanding human neurode-
w
generative disease mechanisms, since human neuro- T
degeneration commonly progresses slowly as well. a
In conclusion, although the initiating mechanisms of w
neurodegeneration in MSA remain to be elucidated, the e
Wdata from the analyses of the M2 mice support the no-
Mtion that oligodendrocytic degeneration as a conse-
aquence of α-synuclein inclusion formation contributes
g
to secondary neuronal degeneration observed in this m
mouse model, thereby suggesting that GCIs play a sim- i
ilar role in MSA. Thus, the M2 mice are compelling mod- (
pels for elucidating mechanisms of disease in MSA andf glial-mediated neuronal degenerative processes in
umans.
xperimental Procedures
eneration of Tg Mice
he generation of Tg mice that express human α-synuclein in CNS
ligodendrocytes driven by the murine CNP promoter was de-
cribed previously (Giasson et al., 2003). Three stable Tg lines car-
ying human α-synuclein were established, and Tg offspring were
dentified by Southern blot analysis using mouse tail DNA. How-
ver, only the M2 line expressed sufficient human α-synuclein to
e significantly detected by immunoblots using human-specific
nti-α-synuclein antibodies from brain homogenates, and a homo-
ygous Tg lineage was identified by quantitative Southern blot
nalysis and verified by backcrossing to non-Tg mice.
solation of RNA and Northern Blotting
otal brain RNA from non-Tg and M2 Tg mice or the mouse prion
rotein promoter (line M7) (Giasson et al., 2002) was isolated using
RIzol reagent (Invitrogen Life Technologies, Carlsbad, CA). The
mounts of RNA were determine by optical density at λ = 260 nm.
NA (10 or 100 g) was electrophoresed on 1% formaldehyde
garose gel and blotted onto Hybond-N nitrocellulose membrane
Amersham Biosciences, Piscataway, NJ). Prehybridization and hy-
ridization were performed in Church buffer (0.5 M sodium phos-
hate [pH 7.2], 1 mM EDTA, 7% SDS) and 0.5 mg/ml salmon sperm
NA at 65°C. The membranes were incubated with an equal
mount of 32P-labeled probes generated by random oligonucleo-
ide priming and extension of isolated full-length mouse and human
-synuclein cDNAs. The membranes were washed with 0.1% SDS/
.1× SSC (15 mM NaCl, 1.5 mM Na citrate [pH 7.0]) at 65°C, air
ried, and exposed to a PhosphorImager plate (Amersham Biosci-
nces, Piscataway, NJ).
n Situ Hybridization
hree specific oligonucleotide probes were designed for human
nd mouse α-synuclein. The two 40 base probes used to specifi-
ally detect the Tg transcript of human α-synuclein are TGGCT
GCAACTAGAAGGCACAGTCGAGGCTGATCAGCGG, complemen-
ary to the BGH sequence, and CCCCTCGAGGTCGACGGTATCG
TAAGCTTGGATGGAACA, complementary to the pcDNA3.1 plas-
id sequence. The 40 base probe specific for mouse α-synuclein
sed is GGGGAGCACCGGGATGCTGAGGGGCAGGTACAGGACG
CG, complementary to bases 141 to 180 from the terminal of exon
of the mouse α-synuclein sequence (GenBank accession number
F179272).
Labeling of probes with [α-33P]dATP and in situ hybridization was




he accelerating rotarod treadmill (Ugo Basile, Italy) was used to
nalyze motor function of M2 mice. Mice were given three trials
ith 45 min intertrial intervals on each of 2 consecutive days for
weeks. Each animal’s endurance time (AET) was recorded, and
he average of AETs is calculated in Figure 2. Sixty-six M2 mice
ere used for the rotarod test (30 male and 34 female), and 62 non-
g mice were used for comparison (28 male and 34 female). In
ddition, 6-week-old M2 (n = 14) and non-Tg control mice (n = 10)
ere habituated on the rotarod and then were tested consecutively
very week from 7 weeks of age until 32 weeks of age.
ire Hanging Grip Strength Test
ice were placed with their forepaws on a horizontal wire and were
llowed to grasp the wire and remain suspended. Each mouse was
iven two trials with an intertrial interval of 2 hr. The total time the
ice remained hanging on the wire was recorded as hanging times
n seconds. Fifty-one M2 mice were used for this grip strength test
24 male and 27 female), and 45 non-Tg mice were used for com-
arison (22 male and 23 female).
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857Anti--Synuclein Antibodies
Syn204 is a Mab raised against recombinant human α-synuclein
that selectively recognizes a human α-synuclein epitope between
amino acid residues 87 and 110 (Giasson et al., 2000). SNL1 is a
rabbit polyclonal antibody raised against a synthetic peptide corre-
sponding to amino acids 104–119 in α-synuclein. SNL1 detects
both mouse and human α-synuclein (Giasson et al., 2000). LB509
is a Mab that recognizes an epitope that includes amino acid resi-
dues 115–122 in human α-synuclein. LB509 does not react with
mouse α-synuclein because of amino acid differences with human
α-synuclein (Baba et al., 1998; Jakes et al., 1999). 7544, which
specifically recognizes mouse α-synuclein, is a gift from Dr. P.J.
Kahle (Adolf Butenandt Institute, Germany) (Kahle et al., 2000).
Analysis of Total -Synuclein Protein and Immunoblot Analyses
Brains and spinal cords were dissected after mice were lethally
anesthetized. For total protein extracts, CNS tissues were weighed
and homogenized in 2% SDS buffer (2% SDS and 50 mM Tris-HCl
[pH 7.5]) with protease inhibitor cocktail (1 mM PMSF and 1 g/ml
each of pepstatin-A, leupeptin, TPCK, TLCK, and soybean trypsin
inhibitor). Protein concentration was determined using bicinchoni-
nic acid assay (BCA) (Pierce, Rockford, Il). After the addition of SDS
sample buffer, equal amounts of each sample were resolved on
13% SDS polyacrylamide gels, transferred onto nitrocellulose
membranes, and processed for immunoblot analyses as previous
described (Higuchi et al., 2002).
Serial Extraction of -Synuclein in Mouse and MSA CNS
Mouse CNS was dissected into cerebrum, cerebellum, brain stem,
and spinal cord. Each part of the CNS tissue was weighed and
homogenized in 2 ml/g of high-salt (HS) buffer (50 mM Tris-HCl [pH
7.5], 10 mM EGTA, 5 mM MgSO4, 750 mM NaCl, and 20 mM NaF)
with protease inhibitor cocktail and centrifuged at 100,000 × g for
30 min at 4°C, where the supernatant was used as the HS-soluble
fraction. The pellet was homogenized in 1 M sucrose in Tris-HCl
(pH 7.6) and centrifuged at 100,000 × g for 30 min at 4°C to remove
myelin and any related lipids. The resulting pellet was dissolved in
RIPA (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 5 mM EDTA, 1%
NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) with protease
inhibitors at 2 ml per gram wet weight of brain tissue and centri-
fuged at 100,000 × g for 30 min at 4°C. The RIPA-soluble superna-
tant was used as RIPA fraction. The pellet was then reextracted in
70% formic acid (FA) by sonication. Protein concentrations of HS
and RIPA samples were determined using the BCA assay. FA sam-
ples were dried and resuspended in SDS sample buffer with vol-
umes equivalent to 1 ml per gram wet weight of tissue. Immunoblot
analyses were conducted as described above.
Brain tissues of MSA and control patients were sequentially
extracted into HS, RIPA, and FA fractions to examine insoluble
α-synuclein as described above for mouse CNS.
Immunohistochemical and Immunofluorescence Analyses
of M2 Mice and Patients with MSA
Mice were perfused transcardially with phosphate-buffered saline
(PBS) after being lethally anesthetized. Brains and spinal cords
were fixed in 10% neutral buffered formalin or 70% ethanol/150
mM NaCl. Following paraffin infiltration, 6 m thick sections were
prepared. Sections were blocked with 2% fetal bovine serum in
0.1 M Tris (pH 7.5) and incubated overnight at 4°C with primary
antibodies: anti-α-synuclein antibodies (Syn204, SNL1, LB509,
7544), a Mab specific for hyperphosphorylated NF-H (RMO24)
(Schmidt et al., 1991), anti-GFAP antibody (DAKO, Denmark), or
anti-GAP43 antibody (Sigma, St. Louis, MO). Sections were reacted
with biotinylated-conjugated secondary antibodies and developed
with diaminobenzidine (DAB) using Vectastain ABC kit (Vector
Laboratories, Burlingame, CA) as previously described (Trojanow-
ski et al., 1989). Brain tissues of five autopsy-confirmed MSA pa-
tients (Tu et al., 1998; Gilman et al., 1999) and five age-matched
controls also were examined by immunohistochemistry.
Double-labeling immunofluorescence study was conducted to de-
monstrate the colocalization of the human α-synuclein transgene and
endogenous CNP in oligodendrocytes. To do this, M2 and non-
Tg mice were serially perfused with 10 ml of PBS, 25 ml of 3%paraformaldehyde in 0.1 M phosphate buffer (PB; pH 7.5), 25 ml of
3% paraformaldehyde in 50 mM sodium borate buffer (pH 9.0), and
30 ml of 10% sucrose in 0.1 M PB as described elsewhere (Higuchi
et al., 2002). The 15 m thick sections of frozen brain and spinal
cord were double immunostained with anti-α-synuclein (SNL1) and
anti-CNP antibodies.
Quantitative Analysis of Neurons and Oligodendrocytes
The total number of neurons in the L2 lumbar spinal cord as well
as dopaminergic neurons in the substantia nigra was counted on
sections from 24-month-old M2 and age-matched non-TG mice
(each for n = 3, 8 sections from each mouse). Cells were visualized
by immunostaining with NeuN (Chemicon, Temecula, CA), an anti-
body that labels neuronal nuclei, and tyrosine hydroxylase (TH)
(Pel-Freese, Brown Deer, WI). Quantitative analyses were con-
ducted on the photographs that cover entire area of interest with an
image analysis software, ImageProPlus (Media Cybernetics, Silver
Spring, MD). For oligodendrocyte analysis, cells were visualized by
immunostaining with anti-CNP antibody. The total number of cells
in the lumbar spinal cord sections from the M2 and non-TG mice
(each for n = 3, 8 sections) was manually counted.
Transmission EM
M2 and control mice at 10 and 24 months of age (n = 3 of each)
were analyzed by transmission EM. The mice were deeply anesthe-
tized and sacrificed by cardiac perfusion using 0.1 M cacodylate
buffer (pH 7.4), followed by 4% paraformaldehyde and 2% glutaral-
dehyde. Cerebrum, pons, cerebellum, and lower thoracic spinal
cord were fixed for 18 hr. Tissues were postfixed with 2% osmium
tetraoxide for 1 hr and dehydrated and embedded in Epon. Ultra-
thin sections were cut and observed with a Joel 1010 transmission
electron microscope (Peabody, MA).
Preembedding Immuno-EM
M2 and control mice at 10 and 24 months of age (n = 3 of each)
were anesthetized and perfused with 0.1 M cocadylate buffer (pH
7.5), followed by 2% paraformaldehyde and 0.5% glutaraldehyde.
Cerebrum, pons, cerebellum, and spinal cord tissues were fixed for
6 hr, washed in PBS, and cut into 50 m thick sections with a
vibratome. The sections were incubated in 0.1% sodium borohy-
dride in PBS for 15 min and blocked with a solution of 5% fetal
bovine serum, 1% bovine serum albumin, and 0.2% cold water fish
skin gelatin in PBS for 2 hr. The sections then were incubated over-
night at 4°C with primary antibodies: anti-α-synuclein antibodies
(Syn204, LB509, or SNL1) or anti-synaptophysin antibody (Co-
vance, Richmond, CA). The sections were incubated with biotiny-
lated-conjugated secondary antibodies and developed with di-
aminobenzidine using Vectastain ABC kit as described above. The
sections were silver enhanced as described by Rodriguez et al.
(1984). The sections were dehydrated and embedded in epoxy
resin. Ultrathin sections were cut and observed using a Joel 1010
electron microscope.
Supplemental Data
The Supplemental Data include two supplemental figures and can
be found with this article online at http://www.neuron.org/cgi/
content/full/45/6/847/DC1/.
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